This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Sep;1(6):785-6.

doi: 10.1001/jamaoncol.2015.2379.

Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No Harm

Charles D Blanke¹, Erik K Fromme²

Affiliations

Affiliations

¹ Division of Hematology & Medical Oncology, Knight Cancer Institute & Oregon Health and Science University, Portland.
² Division of Hematology & Medical Oncology, Knight Cancer Institute & Oregon Health and Science University, Portland2Palliative Care Service, Oregon Health & Science University, Portland.

PMID: 26203585
DOI: 10.1001/jamaoncol.2015.2379

Comment

Chemotherapy Near the End of Life: First--and Third and Fourth (Line)--Do No Harm

Charles D Blanke et al. JAMA Oncol. 2015 Sep.

. 2015 Sep;1(6):785-6.

doi: 10.1001/jamaoncol.2015.2379.

Authors

Charles D Blanke¹, Erik K Fromme²

Affiliations

¹ Division of Hematology & Medical Oncology, Knight Cancer Institute & Oregon Health and Science University, Portland.
² Division of Hematology & Medical Oncology, Knight Cancer Institute & Oregon Health and Science University, Portland2Palliative Care Service, Oregon Health & Science University, Portland.

PMID: 26203585
DOI: 10.1001/jamaoncol.2015.2379

No abstract available

PubMed Disclaimer

Comment on

Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Prigerson HG, et al. JAMA Oncol. 2015 Sep;1(6):778-84. doi: 10.1001/jamaoncol.2015.2378. JAMA Oncol. 2015. PMID: 26203912 Free PMC article.

Similar articles

Evaluating Chemotherapy at the End of Life.
Buiting HM, van den Heuvel MM. Buiting HM, et al. JAMA Oncol. 2016 Jan;2(1):143-4. doi: 10.1001/jamaoncol.2015.4108. JAMA Oncol. 2016. PMID: 26767556 No abstract available.
Evaluating Chemotherapy at the End of Life.
Provenzano AF, Carvajal RD. Provenzano AF, et al. JAMA Oncol. 2016 Jan;2(1):142-3. doi: 10.1001/jamaoncol.2015.4105. JAMA Oncol. 2016. PMID: 26767555 No abstract available.
Evaluating Chemotherapy at the End of Life.
Frickhofen N, Maier BO. Frickhofen N, et al. JAMA Oncol. 2016 Jan;2(1):142. doi: 10.1001/jamaoncol.2015.4102. JAMA Oncol. 2016. PMID: 26767554 No abstract available.
Chemotherapy at end-of-life: an integration of oncology and palliative team.
Chan WL, Lam KO, Siu WK, Yuen KK. Chan WL, et al. Support Care Cancer. 2016 Mar;24(3):1421-7. doi: 10.1007/s00520-015-3031-z. Epub 2015 Nov 25. Support Care Cancer. 2016. PMID: 26604192 Review.
[Managing nausea and vomiting in thoracic oncology].
Le Moulec S, Vedrine L. Le Moulec S, et al. Rev Pneumol Clin. 2008 Apr;64(2):76-80. doi: 10.1016/j.pneumo.2008.04.001. Epub 2008 Jun 6. Rev Pneumol Clin. 2008. PMID: 18589287 Review. French.

See all similar articles

Cited by

End-of-life care in cancer patients: how much drug therapy and how much palliative care? Record linkage study in Northern Italy.
Formoso G, Marino M, Guberti M, Grilli RG. Formoso G, et al. BMJ Open. 2022 May 6;12(5):e057437. doi: 10.1136/bmjopen-2021-057437. BMJ Open. 2022. PMID: 35523497 Free PMC article.
Physician Influence on Variation in Receipt of Aggressive End-of-Life Care Among Women Dying of Ovarian Cancer.
Mullins MA, Uppal S, Ruterbusch JJ, Cote ML, Clarke P, Wallner LP. Mullins MA, et al. JCO Oncol Pract. 2022 Mar;18(3):e293-e303. doi: 10.1200/OP.21.00351. Epub 2021 Sep 28. JCO Oncol Pract. 2022. PMID: 34582262 Free PMC article.
"How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
Simmons C, McMillan DC, Tuck S, Graham C, McKeown A, Bennett M, O'Neill C, Wilcock A, Usborne C, Fearon KC, Fallon M, Laird BJ; IPAC Study Group. Simmons C, et al. Oncologist. 2019 Sep;24(9):e960-e967. doi: 10.1634/theoncologist.2018-0474. Epub 2019 Apr 11. Oncologist. 2019. PMID: 30975922 Free PMC article.
Cancer treatment in the last 6 months of life: when inaction can outperform action.
Gyawali B, Niraula S. Gyawali B, et al. Ecancermedicalscience. 2018 Apr 18;12:826. doi: 10.3332/ecancer.2018.826. eCollection 2018. Ecancermedicalscience. 2018. PMID: 29743946 Free PMC article.
A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study.
Chanez B, Bertucci F, Gilabert M, Madroszyk A, Rousseau F, Perrot D, Viens P, Raoul JL. Chanez B, et al. Support Care Cancer. 2017 Sep;25(9):2715-2722. doi: 10.1007/s00520-017-3680-1. Epub 2017 Mar 28. Support Care Cancer. 2017. PMID: 28353038

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information